NAD+ side effects.

NAD+ side effects: pain, nausea and infusion discomfort

Injection pain and discomfort, nausea, abdominal cramping, diarrhea, vomiting, chest pressure and a faster heartbeat have been reported with direct NAD+ administration. The route and study setting matter. Small injection trials and supervised infusions do not provide one reliable side-effect percentage for every vial, pen or spray. [1] [2]

These are reported symptoms, not a prediction that each person will experience all of them. A reaction can also come from the formulation, contamination, an incorrect amount or the administration procedure. Severe shaking, breathing difficulty or chest pain should not be dismissed as a normal stage of treatment.

Injection pain and local reactions

Pain and discomfort were the most consistent complaints in a small 2026 injection study. Its direct NAD+ groups included six subcutaneous, four intramuscular and five intravenous recipients within a larger nine-group trial. Participants received 100 mg under supervision on three consecutive days. The report was a preprint, with very small groups and qualitative descriptions of symptoms. [1]

That evidence can identify discomfort as something to watch for, but it cannot provide a dependable NAD+ population rate. Percentages from the same paper’s separate NR-only trial concern a different compound. They should not be presented as NAD+ side-effect frequencies.

A brief sore spot and a worsening inflamed area require different responses. Redness that spreads, increasing swelling, red streaks, drainage or a fever warrant prompt medical assessment. A painful area should not become the site for another injection. General injection guidance also advises using healthy skin and changing sites. [3]

If discomfort keeps recurring, the amount, concentration, formulation and technique need review together. Simply moving to a new spot or using more liquid does not establish that the product is suitable for injection.

Nausea, abdominal cramps, diarrhea and vomiting

A small clinic-record study described moderate to severe infusion symptoms in its six NAD+ recipients. The reported symptoms included abdominal cramps, nausea, vomiting, diarrhea, throat discomfort, chest pressure and increased heart rate. The participants received 500 mg IV on four consecutive days. [2]

Six selected clients are too few to establish how frequently these symptoms occur across the wider population. The report also does not show that every route or concentration has the same tolerability. An IV observation cannot supply a nausea rate for a nasal spray.

The symptoms in that study resolved when the infusions ended. That observation is not permission to wait through severe or unfamiliar symptoms. During supervised treatment, report them immediately so the treating professional can assess the reaction. Persistent vomiting, inability to keep fluids down or severe abdominal pain needs medical attention. [4]

There is no validated over-the-counter pretreatment routine in these studies that makes an unsuitable NAD+ preparation safe. Taking another medicine to suppress a warning symptom can obscure the problem rather than resolve its cause.

Chest pressure, breathing symptoms and heart-rate changes

Chest pain or pressure, difficulty breathing and fainting need urgent assessment. Do not assume a reaction is harmless because a similar symptom appears in an infusion report. Severe chest pressure or shortness of breath is a reason to call emergency services; do not drive yourself while faint or severely unwell. [4]

A feeling of a racing heart does not identify its cause. It may occur alongside pain or other symptoms, but the individual situation still needs evaluation. Stopping a supervised administration and having the clinician assess the person is different from attempting to diagnose and manage the reaction alone.

The small studies did not establish a universal heart-rate or blood-pressure threshold at which a consumer should change an NAD+ amount. Their monitoring arrangements should not be converted into instructions for self-administering an IV infusion.

Severe chills and shaking are not a “detox” reaction

FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injectable products, with some people requiring medical treatment. The agency describes these reactions as consistent with excessive endotoxin exposure. Its alert warns about unsuitable ingredients being used to prepare products intended to be sterile. [5]

A separate January 2026 FDA warning letter described three patients who developed symptoms including uncontrollable shaking, shivers, low blood pressure and body aches after a compounded NAD+ product. An unopened vial from that lot tested at 3,360 EU/mL of bacterial endotoxins. This was an identified product-quality failure, not evidence of a beneficial cleansing process. [6]

Severe shaking or feeling suddenly very unwell after administration requires prompt medical help, particularly with fever, weakness, breathing difficulty or faintness. Do not continue using the suspect product while deciding whether the reaction will pass. Keep its packaging and lot information available for the treating professional and any adverse-event report.

Good hand hygiene cannot remove endotoxins already present in a preparation. Product quality and clean handling solve different problems; both matter.

A tenfold concentration difference can change the amount

The 100 mg injection study used 2 mL, which equals 50 mg/mL. The pen contains 1,500 mg in 3 mL at 500 mg/mL, ten times that concentration. The same liquid volume therefore contains ten times as much NAD+. Calculate the volume from the concentration of the product being measured. [1] [7]

Volume containing 100 mg at each concentration. This comparison shows how the same amount occupies different liquid volumes.

The vial contains 1,000 mg of dry powder in a 10 mL container. Its final solution volume determines the concentration after preparation. The NAD+ calculator converts vial milligrams, final solution volume and an entered target amount into milliliters and U-100 syringe units.

Clean handling and intact equipment

Use a new sterile needle and syringe for every injection, and prevent contact with used equipment. CDC guidance identifies reuse and contamination of medication containers as causes of serious infection. A changed needle does not make an already used syringe clean. [8]

• Read the label before use. Check the ingredient, concentration, expiry date and handling instructions.
• Keep preparation clean. Wash hands, use a clean working area and keep sterile parts protected. Use the appropriate skin preparation and allow it to dry.
• Reject damaged supplies. Broken sterile wrapping, a missing cap, a damaged container or questionable sterility is a reason not to use the item.
• Keep equipment for one person. Do not share needles, syringes or pen devices. Put used sharps into an appropriate sharps container. [3] [9]

These general practices reduce avoidable contamination. They do not turn a research material into an approved injectable medicine or establish that repeated entry into a particular vial is suitable. Do not pool leftovers from containers to create a later administration. [8]

Storage and nasal-spray handling

The powder and prepared liquid have different storage requirements. The lot-specific powder report specifies −20°C (−4°F), tightly closed, dry and protected from light. The pen and nasal handling information specifies refrigeration at 2–8°C (36–46°F), with protection from light and no freezing. [7]

The pen’s stated discard conditions include freezing, new discoloration or cloudiness. Do not warm, shake or dilute a visibly changed product to make it appear usable again. A clear appearance also cannot prove that a preparation is free of microbes or endotoxins.

Follow the preparation-specific storage and discard instructions after opening or mixing. The powder retest date and the number of portions do not set the usable life of a prepared product.

The nasal bottle contains 30 mg in 200 sprays, or 150 mcg per spray. Keep it upright, capped and protected from light. Persistent nasal irritation or a new reaction after use is a reason to stop and seek medical advice. [7]

What the vial COA can confirm

The supplied powder-lot report records 99.81% HPLC area purity, endotoxin at 0.05 EU/mg and no growth in the reported sterility test. It covers two sampled vials from a lot of 250. The displayed PDF is clearly marked as a redacted copy; its analytical results, dates and lot information are retained. [10]

HPLC area purity does not measure the exact milligrams in each vial. The report is also not a finished-pen or finished-spray test, and no documented connection establishes that those formats use the tested powder lot. Results from sampled containers cannot guarantee later handling conditions or every future batch.

The certificate therefore belongs alongside the product specifications, with its scope intact. It does not independently establish that a home-prepared solution is suitable for human injection. The product and COA comparison keeps these distinctions visible.

Medical conditions, medicines and longer-term use

Small studies in selected adults cannot establish safety during pregnancy, breastfeeding or childhood. They also do not provide a complete interaction list for direct NAD+ or prove that a long course is safe for someone with significant medical conditions.

A clinical review should consider the ingredient and formulation, medication list, allergies and the reason for treatment. A known reaction to an ingredient matters even when that ingredient is a preservative rather than NAD+ itself.

NAD+, NADH, NR and niacin are different formulations. Side effects and dosing rules from one should not be copied to another. Likewise, the absence of serious treatment-related events in a short pilot does not exclude rare reactions or problems after prolonged exposure. A mild first administration cannot guarantee later tolerance. [1]